Leukemia & Lymphoma最新文献_第5页

Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-03 DOI: 10.1080/10428194.2025.2457553

Rahul Lakhotia, Christopher Melani, Kieron Dunleavy, Stefania Pittaluga, Sanjal Desai, Mark A Ahlman, Nicole Lucas, Seth M Steinberg, Elaine S Jaffe, Wyndham H Wilson, Mark Roschewski

{"title":"Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas.","authors":"Rahul Lakhotia, Christopher Melani, Kieron Dunleavy, Stefania Pittaluga, Sanjal Desai, Mark A Ahlman, Nicole Lucas, Seth M Steinberg, Elaine S Jaffe, Wyndham H Wilson, Mark Roschewski","doi":"10.1080/10428194.2025.2457553","DOIUrl":"https://doi.org/10.1080/10428194.2025.2457553","url":null,"abstract":"Immune cells within the lymphoma tumor microenvironment promote immune evasion and are rational therapeutic targets. Alemtuzumab targets CD52 expressed on malignant B-cells and infiltrating nonmalignant T-cells. We evaluated the safety and efficacy of alemtuzumab with DA-EPOCH-R in 48 patients with relapsed/refractory aggressive B-cell lymphoma. Febrile neutropenia occurred in 18% of cycles and serious infections in 21% of patients. Responses were observed in 30 (62%) patients, including 12 (80%) patients with classical HL and 3 (75%) patients with T-cell/histiocyte-rich large B-cell lymphoma (THRLCL). Seventeen (35%) patients achieved complete responses, and 12 (25%) were bridged to consolidation. The 2-year progression-free survival (PFS) and overall survival were 22.1% (95% CI, 11.5-34.7%) and 45.2% (95% CI, 34.3-58.9%), respectively. The 2-year PFS for HL and THRLCL patients was 35% and 50%, respectively. Alemtuzumab can be safely combined with DA-EPOCH-R in relapsed/refractory aggressive B-cell lymphomas and can induce durable responses in patients with T-cell-rich microenvironments.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-12"},"PeriodicalIF":2.2,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

T-cell neoplasias and secondary malignancies after CAR-T cell therapy: current knowledge, risk factors, and implications from CAR-T engineering strategies.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-02 DOI: 10.1080/10428194.2025.2460043

Katie Maurer, Caron A Jacobson

{"title":"T-cell neoplasias and secondary malignancies after CAR-T cell therapy: current knowledge, risk factors, and implications from CAR-T engineering strategies.","authors":"Katie Maurer, Caron A Jacobson","doi":"10.1080/10428194.2025.2460043","DOIUrl":"https://doi.org/10.1080/10428194.2025.2460043","url":null,"abstract":"Widespread use of CAR-T cell therapies for treatment of B cell malignancies has resulted in a frameshift in treatment strategies and improved patient outcomes since the first CAR-T product was FDA approved in 2017. Currently over 30,000 patients have been treated with approved CAR-T cell products, with many more likely to be treated in future, both as standard of care therapy as well as on clinical trials. As more patients are treated, development of rare complications has begun to emerge, and the incidence of second primary malignancies after CAR-T cell therapy is evolving from a hypothetical to a realized concern. Furthermore, in November 2023, the FDA issued a warning regarding the potential for CAR-T cell-derived T cell neoplasias to arise as a result of CAR-T manufacturing. Here we review patient risk factors for development of second primary malignancies including T cell neoplasias, CAR-T engineering strategies that may increase this risk, and the current body of literature surrounding incidence of second primary malignancies and case reports of T cell neoplasias arising after CAR-T cell therapy.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143080566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early impact of treatment modifications adopted for acute lymphoblastic leukemia during SARS-CoV-2 pandemic; a single center experience and lessons for LMICs. 在 SARS-CoV-2 大流行期间对急性淋巴细胞白血病采取的治疗调整的早期影响；一个单一中心的经验和对低收入和中等收入国家的启示。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-01 Epub Date: 2024-10-09 DOI: 10.1080/10428194.2024.2411432

Esraa Maged Mohammad, Moatasem El-Ayadi, Ahmad Kamel, Emad Ebeid

{"title":"Early impact of treatment modifications adopted for acute lymphoblastic leukemia during SARS-CoV-2 pandemic; a single center experience and lessons for LMICs.","authors":"Esraa Maged Mohammad, Moatasem El-Ayadi, Ahmad Kamel, Emad Ebeid","doi":"10.1080/10428194.2024.2411432","DOIUrl":"10.1080/10428194.2024.2411432","url":null,"abstract":"Treatment modifications adopted during pandemic aimed at reducing infection, myelosuppression, and optimizing hospital resources. This study evaluated outcomes for pediatric patients with ALL who had treatment modifications during pandemic compared to historical cohorts at the National Cancer Institute, Cairo University, Egypt. Bi-directional cohort study included 378 patients. Treatment modifications included omission of specific drugs or adjusting chemotherapy schedules to 6-mercaptopurine/methotrexate. Median follow-up were 45.1 and 43.2 months, for cohorts (A) and (B), respectively. The three-year overall survival were 84.9% and 87.5% (p = .48) and three-year relapse free survival were 82.8% and 86.5% (p = .11) for cohorts (A) and (B), respectively. Infection-related mortality was 11% and 4.4% for cohorts (A) and (B), respectively (p = .03). Treatment modifications adopted during the pandemic did not adversely affect the outcome of patients with ALL and notably reduced infection-related deaths. Longer follow-up is warranted to validate these findings.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"306-312"},"PeriodicalIF":2.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142391626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating early response assessment in extranodal natural killer/T-cell lymphoma by analyzing ΔSUVlbm between baseline and interim ¹⁸F-FDG PET/CT scans. 通过分析基线与中期18F-FDG PET/CT扫描之间的ΔSUVlbm，评估结节外自然杀伤/T细胞淋巴瘤的早期反应评估。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-01 Epub Date: 2024-10-15 DOI: 10.1080/10428194.2024.2416026

Lei Yang, Li-Jie Zeng, Shuang Wang, Li-Qiang Wei, Jing Yang, Mei Li, Liang Wang

{"title":"Evaluating early response assessment in extranodal natural killer/T-cell lymphoma by analyzing ΔSUVlbm between baseline and interim 18F-FDG PET/CT scans.","authors":"Lei Yang, Li-Jie Zeng, Shuang Wang, Li-Qiang Wei, Jing Yang, Mei Li, Liang Wang","doi":"10.1080/10428194.2024.2416026","DOIUrl":"10.1080/10428194.2024.2416026","url":null,"abstract":"To determine the optimal variation in SUVlbm via 18F-FDG PET/CT imaging between the baseline and interim stages, and assess early response among patients with extranodal natural killer/T-cell lymphoma (ENKTCL) of 5-DS score ≥ 4, 20 patients after four cycles of chemotherapy were retrospectively enrolled and received re-biopsy targeting PET-positive residual masses. The optimal cutoff value for evaluating early response assessment was 66.75% for ΔSUVlbm%, with the area under curve of 0.985. All patients with a 5-DS score of 4 exhibited negative results upon re-biopsy. During follow-up, the median PFS of patients characterized by ΔSUVlbm% ≥66.75% and <66.75% were unreached and 10 months, respectively. Utilizing ΔSUVlbm% between baseline and interim 18F-FDG PET/CT scans can effectively identify a subset of patients who were visually analyzed as false positives(5-DS ≥ 4), which was confirmed by interim biopsy results, thus serving as a crucial indicator for early assessment of treatment outcomes in patients with ENKTCL.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"262-269"},"PeriodicalIF":2.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142469017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML. IDH突变型急性髓细胞性白血病的HMA/VEN治疗调整及相关结果

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-01 Epub Date: 2024-10-14 DOI: 10.1080/10428194.2024.2411436

Kuo-Kai Chin, Andriy Derkach, Christopher Famulare, Gaurav K Gupta, P Dayand Borge, Mark B Geyer, Aaron D Goldberg, Tamanna Haque, Jae H Park, Lindsey E Roeker, Martin S Tallman, Maximilian Stahl, Eytan M Stein

{"title":"HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML.","authors":"Kuo-Kai Chin, Andriy Derkach, Christopher Famulare, Gaurav K Gupta, P Dayand Borge, Mark B Geyer, Aaron D Goldberg, Tamanna Haque, Jae H Park, Lindsey E Roeker, Martin S Tallman, Maximilian Stahl, Eytan M Stein","doi":"10.1080/10428194.2024.2411436","DOIUrl":"10.1080/10428194.2024.2411436","url":null,"abstract":"Hypomethylating agents (HMA) and venetoclax (VEN) are commonly used in patients with IDH-mutated (IDHm) acute myeloid leukemia (AML) ineligible for induction chemotherapy. While prior studies demonstrated high response and survival rates with HMA/VEN in IDHm AML, the impact of treatment modifications in real-world settings is unclear. We retrospectively reviewed 89 IDHm AML patients treated with HMA/VEN from January 2018 to June 2023. CR/CRi rates were 76% in newly diagnosed (ND) and 55% in relapsed/refractory (R/R) patients, and median overall survival was 29.2 months (ND) and 17.1 months (R/R), respectively. Treatment modifications were common. Early VEN reductions were associated with lower response rates but not worse survival. Prolonged cycles were not associated with worse response rates or survival. Significant neutropenia and ED visits or unplanned hospitalizations were considerable before and after CR/CRi, though febrile neutropenia decreased afterward. HMA/VEN is efficacious, with treatment modifications not affecting survival, though long-term toxicities are notable.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"270-278"},"PeriodicalIF":2.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142469020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MG4101, an allogeneic natural killer cell, in patients with relapsed or refractory acute myeloid leukemia: a pilot study. 异体自然杀伤细胞 MG4101 在复发或难治性急性髓性白血病患者中的应用：一项试验研究。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-01 Epub Date: 2024-10-22 DOI: 10.1080/10428194.2024.2414903

Sang-A Kim, Miyoung Jung, Hyojin Kim, Ja Min Byun, Junshik Hong, Dong-Yeop Shin, Inho Kim, Sung-Soo Yoon, Sung Yoo Cho, Yu Kyeong Hwang, Youngil Koh

{"title":"MG4101, an allogeneic natural killer cell, in patients with relapsed or refractory acute myeloid leukemia: a pilot study.","authors":"Sang-A Kim, Miyoung Jung, Hyojin Kim, Ja Min Byun, Junshik Hong, Dong-Yeop Shin, Inho Kim, Sung-Soo Yoon, Sung Yoo Cho, Yu Kyeong Hwang, Youngil Koh","doi":"10.1080/10428194.2024.2414903","DOIUrl":"10.1080/10428194.2024.2414903","url":null,"abstract":"We evaluated the safety and efficacy of allogeneic, ex-vivo expanded, NK cells, MG4101, in patients with refractory or relapsed AML. The relationship between immunological characteristics and clinical responses was analyzed. Between April 2018 and February 2020, 11 patients (male:female = 5:6) were treated with MG4101. Of eight evaluable patients, two (25.0%) showed partial response and two (25.0%) showed stable disease. The median overall survival was 3.4 months (95% confidence interval [95% CI], 2.5-4.3 months), and the allogeneic hematopoietic stem cell transplantation (HSCT) censored duration of response was 2.9 months (95% CI, 1.5-4.4 months). Two patients underwent HSCT after MG4101 treatment. Except for one grade 3 infusion-related reaction, no serious adverse events were observed. The sum of activating KIRs in responders tended to be higher than that in non-responders. Analyses of NKRL and KIR highlighted the importance of immunological mechanisms in treating myeloid neoplasms.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"298-305"},"PeriodicalIF":2.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142469024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inter-racial genetic differences in myelofibrosis: a diverse inner-city center analysis. 骨髓纤维化的种族间遗传差异：多样化内城中心分析。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-01 Epub Date: 2024-10-21 DOI: 10.1080/10428194.2024.2414121

Josette Kamel, John Yan, Bradley Rockwell, Mendel Goldfinger, Eric J Feldman, Marina Y Konopleva, Ioannis Mantzaris, Aditi Shastri, Noah Kornblum, Kira Gritsman, Alejandro Sica, Nishi Shah, Dennis Cooper, Amit Verma, Swati Goel

引用次数: 0

Isavuconazole in treatment of invasive fungal disease in children with malignancy or undergoing cellular therapy. 伊沙夫康唑用于治疗患有恶性肿瘤或正在接受细胞疗法的儿童的侵袭性真菌病。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-01 Epub Date: 2024-10-16 DOI: 10.1080/10428194.2024.2416021

Jan Styczynski, Krzysztof Czyzewski, Ewa Demidowicz, Magdalena Wozniak, Marcin Plonowski, Malgorzata Sawicka-Zukowska, Ewa Bien, Ninela Irga-Jaworska, Tomasz Ociepa, Aleksandra Krolak, Tomasz Urasinski, Lukasz Hutnik, Anna Szmydki-Baran, Aleksandra Minkowska, Katarzyna Pikora, Paweł Laguna, Malgorzata Salamonowicz-Bodzioch, Jowita Fraczkiewicz, Krzysztof Kalwak, Katarzyna Derwich, Olga Zajac-Spychala

引用次数: 0

Indolent relapse after initial aggressive B-cell lymphoma: a single institution experience in the rituximab era. 初发侵袭性 B 细胞淋巴瘤后的隐匿性复发：利妥昔单抗时代单个机构的经验。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-01 Epub Date: 2024-10-18 DOI: 10.1080/10428194.2024.2416563

Daniel Fasser, Katharine Lewis, Connull Leslie, Gavin Cull, Dejan Radeski, Bradley Augustson, Rebecca Howman, David Joske, Julie Crawford, Carolyn Grove, Chan Y Cheah

引用次数: 0

Novel prognostic factors and therapeutic advances in adult acute lymphoblastic leukemia. 成人急性淋巴细胞白血病的新预后因素和治疗进展。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-01 Epub Date: 2024-10-18 DOI: 10.1080/10428194.2024.2416569

Josep-Maria Ribera, Anna Torrent

引用次数: 0